How Megace ES can help your patients

With just 1 teaspoon once daily, Megace ES may help your AIDS patients improve their appetite, gain weight, and improve their sense of well-being.¹

Unintended weight loss

Unintended weight loss is an involuntary decrease in body weight and can be a common disorder in patients with HIV/AIDS.^21,22 For these patients, maintaining adequate caloric intake is especially difficult.^29-31

Unintended weight loss can greatly impact AIDS patients in the following ways:

• Loss of physical function²³

• Significant mortality risk²⁴

• Greater risk of hospitalization¹²

• Depression and withdrawal from daily activities^23,25

Unintended weight loss is also associated with morbidity and reduced quality of life. Even a minimal weight loss of 5% is a predictor of opportunistic infections in the AIDS patient²⁶ and can lead to anorexia or cachexia.

Weight Gain Evaluated in the Pilot Study¹⁸

The weight gain associated with Megace ES and Megace^®* was evaluated in patients with HIV-associated unintended weight loss.

• This trial was conducted as a pilot study using a concentrated suspension of 575 mg/5mL megestrol acetate. Megace ES is available as megestrol acetate 125 mg per mL oral suspension. The initial recommended dose of Megace ES is 625 mg/5 mL

• Randomized, open-label, multicenter pilot study that enrolled 63 AIDS patients. Patients received either Megace ES (575 mg/5 mL) or Megace (800 mg/20 mL) once daily in the morning for 12 weeks

• Those patients receiving megestrol acetate oral suspension 800 mg/20 mL gained an average of 6% of their baseline weight over 12 weeks (7.7lbs)¹⁸

• Safety was similar for each arm of the trial

Consider Megace ES to help your patients

• Increase their appetite

• Gain weight

• Improve their sense of well-being¹

*Megestrol acetate oral suspension.